Kunshi Bioscience: Net profit loss of 20.564 million yuan in the first quarter.

Kunsheng Biology announced that in the first quarter of 2026, the operating income reached 726 million yuan, a year-on-year increase of 45.09%; the net profit attributable to the shareholders of the listed company was a loss of 20.564 million yuan. The change in performance is mainly due to the increase in sales revenue of commercialized drugs compared to the same period last year, leading to an increase in operating income; at the same time, the company actively implemented the "quality improvement and efficiency increase for better returns" action plan, improving research and development and sales efficiency, resulting in a decrease in losses. The company's net profit in Q1 was -0.21 billion, and the net profit in Q4 of 2025 was -2.79 billion. Based on this calculation, the net profit in Q1 continued to be in a loss compared with the previous quarter.